NCT00088218View on ClinicalTrials.gov

Clofarabine vs Clofarabine in Plus With Low-Dose Ara-C in Previously Untreated Patients With Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndromes (MDS).

PHASE2CompletedINTERVENTIONAL
Enrollment

95

Participants

Timeline

Start Date

July 31, 2004

Primary Completion Date

February 29, 2008

Study Completion Date

February 29, 2008

Conditions
Acute Myeloid LeukemiaMyelodysplastic Syndrome
Interventions
DRUG

Clofarabine

1-hour IV infusion 30 mg/m\^2 daily times 5 days (Days 1-5)

DRUG

Ara-C

20 mg/m\^2 subcutaneously daily times 14 days (Days 1-14). On Days 1 to 5 of each course, clofarabine will precede injection of ara-C by approximately 4 hours (+/- 1 hour).

Trial Locations (1)

77030

M.D. Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

Genzyme, a Sanofi Company

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER

NCT00088218 - Clofarabine vs Clofarabine in Plus With Low-Dose Ara-C in Previously Untreated Patients With Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndromes (MDS). | Biotech Hunter | Biotech Hunter